Total Revenue
Regeneron Pharmaceuticals Total Revenue decreased by 7.2% to $3.61B in Q1 2026 compared to the prior quarter. Year-over-year, this metric grew by 19.0%, from $3.03B to $3.61B. Over 4 years (FY 2021 to FY 2025), Total Revenue shows a downward trend with a -2.8% CAGR. This decline may warrant attention — for this metric, higher values are generally preferred.
Analysis
How to read this metric
An increase indicates growing market demand or successful price increases, while a decrease suggests market saturation or competitive pressure.
Detailed definition
The total amount of income generated by the sale of goods or services related to the company's primary operations. For a...
Peer comparison
Peer technology firms typically report this as Net Sales or Total Revenue, reflecting the scale of their market reach.
total_revenueHistorical Data
| Q2 '21 | Q3 '21 | Q4 '21 | Q1 '22 | Q2 '22 | Q3 '22 | Q4 '22 | Q1 '23 | Q2 '23 | Q3 '23 | Q4 '23 | Q1 '24 | Q2 '24 | Q3 '24 | Q4 '24 | Q1 '25 | Q2 '25 | Q3 '25 | Q4 '25 | Q1 '26 | |
|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|
| Value | $5.14B | $3.45B | $4.95B | $2.97B | $2.86B | $2.94B | $3.41B | $3.16B | $3.16B | $3.36B | $3.43B | $3.15B | $3.55B | $3.72B | $3.79B | $3.03B | $3.68B | $3.75B | $3.88B | $3.61B |
| QoQ Change | — | -32.8% | +43.4% | -40.1% | -3.6% | +2.8% | +16.3% | -7.4% | -0.1% | +6.5% | +2.1% | -8.4% | +12.8% | +4.9% | +1.8% | -20.1% | +21.4% | +2.1% | +3.5% | -7.2% |
| YoY Change | — | — | — | — | -44.4% | -15.0% | -31.0% | +6.6% | +10.5% | +14.5% | +0.6% | -0.5% | +12.3% | +10.6% | +10.3% | -3.7% | +3.6% | +0.9% | +2.5% | +19.0% |
Product Breakdown — Share Of Profit Losses In Connection With Commercialization
Regeneron's obligation for Sanofi's share of Libtayo U.S. gross profits, Share Of Profits Losses In Connection With Commercialization are derived from annual filings.
Amounts Recognized In Connection With Up Front Payments, Other, Regeneron's obligation for its share of Sanofi commercial expenses, Regeneron's obligation for Sanofi's share of Libtayo U.S. gross profits, Reimbursement for manufacturing of ex-U.S. commercial supplies, Reimbursement Of Research And Development Expenses, Sales-based milestone earned, Share Of Profit Losses In Connection With Commercialization, Share Of Profits Losses In Connection With Commercialization were previously reported and have since been discontinued or reclassified. Only currently active segments are shown in the chart.
Product Breakdown — Inmazeb
| Segment | Q1 '24 | Q2 '24 | Q3 '24 | Q3 '25 | Q1 '26 |
|---|---|---|---|---|---|
| Other products | — | — | — | $800.00K | $31.30M |
| Lynozyfic | — | — | — | — | $11.20M |
| Inmazeb | $1.00M | $0.00 | $35.60M | — | — |
| Total | $3.15B | $3.55B | $3.72B | $3.75B | $3.61B |
Inmazeb was previously reported and has since been discontinued or reclassified. Only currently active segments are shown in the chart.
Total Revenue at Other Companies
Frequently Asked Questions
- What is Regeneron Pharmaceuticals's total revenue?
- Regeneron Pharmaceuticals (REGN) reported total revenue of $3.61B in Q1 2026.
- How has Regeneron Pharmaceuticals's total revenue changed year-over-year?
- Regeneron Pharmaceuticals's total revenue increased by 19.0% year-over-year, from $3.03B to $3.61B.
- What is the long-term trend for Regeneron Pharmaceuticals's total revenue?
- Over 4 years (2021 to 2025), Regeneron Pharmaceuticals's total revenue has grown at a -2.8% compound annual growth rate (CAGR), from $16.07B to $14.34B.
- What does total revenue mean?
- The total amount of money a company brings in from selling its products and services.